Domain I: The hidden face of antiphospholipid syndrome

Lupus

Volumn 23, Issue 12, 2014, Pages 1320-1323

  Pericleous, C ^a   Rahman, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti domain I antibodies; pregnancy morbidity; thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; IMMUNOGLOBULIN G; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; HUMAN; IN VITRO STUDY; NONHUMAN; PATHOGENICITY; PROTEIN DOMAIN; THROMBOSIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; PHYSIOLOGY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; TOLL-LIKE RECEPTOR 4;

EID: 84908671566     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314540354     Document Type: Conference Paper

References (28)

1. Ioannou Y, Zhang JY, Qi M, et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen beta2-glycoprotein I. Arthritis Rheum 2011; 63: 2774-2782.
2. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998 ; 95: 15542-15546
3. McNeeley PA, Dlott JS, Furie RA, et al. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost. 2001 ; 86: 590-595
4. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002 ; 169: 7097-7103
5. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007 ; 56: 280-290
6. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006 ; 107: 1916-1924
7. Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome. Blood. 2010 ; 116: 1336-1343
8. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005 ; 105: 1540-1545
9. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study. J Thromb Haemost. 2009 ; 7: 1767-1773
10. Andreoli L, Nalli C, Motta M, et al. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: Might it be the reason for their 'innocent' profile?. Ann Rheum Dis. 2011 ; 70: 380-383
11. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007 ; 109: 1490-1494
12. Wahezi DM, Ilowite NT, Wu XX, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of beta2-glycoprotein I. Lupus. 2013 ; 22: 702-711
13. Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. Affinitty-purified antibodies directed to domain I of beta 2GPI are pathogenic in a mouse model of thrombosis. Arthritis Rheum. 2012 ; 64: S740 - S740
14. Pericleous C, Miles J, Esposito D, et al. Evaluating the conformation of recombinant domain I of beta(2)-glycoprotein I and its interaction with human monoclonal antibodies. Mol Immunol. 2011 ; 49: 56-63
15. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost. 2000 ; 84: 388-395
16. Giles I, Pericleous C, Liu X, et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol. 2009 ; 182: 4836-4843
17. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: Proof of concept. J Thromb Haemost. 2009 ; 7: 833-842
18. Agostinis C, Durigutto P, Sblattero D, et al. A non complement-fixing antibody to beta2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood. 2014 ; 123: 3478-3487
19. Colasanti T, Alessandri C, Capozzi A, et al. Autoantibodies specific to a peptide of beta2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood. 2012 ; 120: 3360-3370
20. de Laat B, van Berkel M, Urbanus RT, et al. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: Domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011 ; 63: 3960-3968
21. Pierangeli SS, de Groot PG, Dlott J, et al. Criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus. 2011 ; 20: 182-190
22. Bertolaccini ML, Amengual O, Atsumi T, et al. Non-criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011 ; 20: 191-205
23. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; doi: 10.1016/j.autrev.2014.05.001. [Epub ahead of print].
24. Ioannou Y, Giles I, Lambrianides A, et al. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol. 2006 ; 6: 8-8
25. Banzato A, Pozzi N, Frasson R, et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res. 2011 ; 128: 583-586
26. Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol. 2013 ; 40: 282-286
27. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012 ; 12: 313-317
28. Mondejar R, Gonzalez-Rodriguez C, Toyos-Saenz de Miera FJ, et al. Role of antiphospholipid score and anti-beta2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta. 2014 ; 431C: 174-178